

FOR IMMEDIATE RELEASE

August 17, 2007

Contact: John Wynne, 513-579-9911 x 2407
j.wynne@medpace.com

MEDPACE STRENGTHENS PRESENCE IN CENTRAL EUROPE

CINCINNATI and PRAGUE (August 17, 2007) — Medpace, Inc., a leading global full-service contract research organization, today announced it has completed the acquisition of Monax s.r.o., a regional contract research organization (CRO) headquartered in Prague, Czech Republic. This move strengthens the Medpace presence in Central Europe and expands its capacity to provide full service clinical research management within the Czech Republic and Slovakia. Petr Potuznik, MD, the founder of Monax, will continue to lead Medpace clinical operations for the region.

“We are excited to welcome the Monax team to the Medpace family,” said August Troendle, MD, Medpace Chief Executive Officer. “The expertise of Dr. Petr Potuznik and his highly trained team fit perfectly within our strategic global expansion plan.”

“We have worked closely with Medpace in the past and found that our companies shared a high level of expertise and commitment to quality,” said Potuznik. “Becoming part of the Medpace group allows the Monax team to grow and expand our presence and capabilities throughout the region.”

About Medpace

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry’s most experienced and therapeutically focused team to execute at every level of the company’s operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development — from program planning and execution to product approval.

With more than 500 employees and clinical trial experience in nearly 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

The Medpace group of companies also includes

Imagepace – a centralized imaging laboratory with expertise in cIMT

Medpace Reference Laboratory – a centralized lab with therapeutically specialized testing

Medpace Clinical Pharmacology – a Phase I/IIa unit scheduled to open in Q1, 2008.